GlassScriptPhysician profile
Jennifer Olsen
NPI 1801413943
$6,197.06
in general payments reported to CMS, 2019-2025
27 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $632 · 2022: $977 · 2023: $1,345 · 2024: $2,037 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,587.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,602.72 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $521.74 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $520.39 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $492.12 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $385.33 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $327.65 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $291.54 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $233.05 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $233.02 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $223.77 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.28 | 2022-2025 | Caplyta |
| Tris Pharma INC | $178.98 | 2023-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $132.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.93 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $112.85 | 2022-2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $112.11 | 2024 | Impella |
| Biogen, INC. | $107.59 | 2023-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $68.76 | 2023-2024 | Quviviq |
| Indivior INC. | $66.13 | 2024-2025 | Sublocade, Perseris |
| Lilly USA, LLC | $50.16 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Noven Therapeutics, LLC | $48.87 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $42.72 | 2023-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $41.55 | 2024-2025 | Cobenfy |
| Celltrion USA INC. | $24.47 | 2025 | Vegzelma |
| Braeburn INC. | $14.51 | 2024 | Brixadi |
| Almatica Pharma LLC | $14.39 | 2023 | Sertraline Hcl, Loreev Xr |
| Eisai INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.